Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.39 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14666164 | 0.95 | HIF1A (0.40) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14665999 | 0.93 | HIF1A (0.38) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL3458345 | 0.87 | COXFA4 (0.51) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14665992 | 0.77 | COXFA4 (0.49) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14666309 | 0.77 | COXFA4 (0.49) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14666104 | 0.77 | HIF1A (0.42) | HIF1AEPAS1COXFA4 | |
| SCHEMBL12315572 | 0.77 | COXFA4 (0.48) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14666254 | 0.77 | HIF1A (0.48) | HIF1AEPAS1COXFA4HSP90AA1 | |
| SCHEMBL14666250 | 0.76 | CYP3A4 (0.36) | HIF1A | |
| SCHEMBL12315596 | 0.74 | COXFA4 (0.43) | HIF1AEPAS1COXFA4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HIF1A 887/4885EPAS1 852/4885COXFA4 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.